Great Lakes NeuroTechnologies announced today the product launch of Kinesia ProView™ to visualize motor symptom severity response during programming of deep brain stimulation (DBS) for Parkinson’s disease. Kinesia ProView provides a standardized platform to quantitatively assess how symptoms such as tremor, bradykinesia, and dyskinesias change in response to specific DBS settings during outpatient programming procedures.
[More]
New research reveals that Solanaceae-a flowering plant family with some species producing foods that are edible sources of nicotine-may provide a protective effect against Parkinson's disease. The study appearing today in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, suggests that eating foods that contain even a small amount of nicotine, such as peppers and tomatoes, may reduce risk of developing Parkinson's.
[More]
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
[More]
Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.
[More]
Repetitive transcranial magnetic stimulation (rTMS) is being increasingly explored as a therapeutic tool for movement disorders associated with deficient inhibition throughout the central nervous system. This includes treatment of focal hand dystonia (FHD), characterized by involuntary movement of the fingers either curling into the palm or extending outward.
[More]
St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its Brio, Libra and LibraXP deep brain stimulation systems for managing the symptoms of intractable primary and secondary dystonia, a neurological movement disorder that causes a person's muscles to contract and involuntarily spasm, reducing the ability to control movement.
[More]
Athena Diagnostics, a leader in neurological diagnostics, today announced the clinical availability of new genetic tests to aid the detection of several rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy and certain movement disorders. The lab-developed tests are available through Athena Diagnostics, a business of Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services.
[More]
A small study of 20 people with Parkinson’s disease suggests that “virtual house calls” using Web-based video conferencing provide clinical benefits comparable to in-person physician office visits, while saving patients and their caregivers time and travel.
[More]
A pair of studies tells the tale of how a neuroscientist at Mayo Clinic in Florida helped to discover the first African-American family to have inherited the rare movement disorder dystonia, which causes repetitive muscle contractions and twisting, resulting in abnormal posture.
[More]
Researchers from Ludwig-Maximilians-Universitaet (LMU) in Munich identify a novel signal transduction pathway, which activates the parkin gene and prevents stress-induced neuronal cell death.
[More]
The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), awarded a three-year, $900,000 grant to the Center for Biomedical Imaging Statistics at Emory's Rollins School of Public Health.
[More]
Researchers at the University of California, San Diego School of Medicine say overexpression of a protein called alpha-synuclein appears to disrupt vital recycling processes in neurons, starting with the terminal extensions of neurons and working its way back to the cells' center, with the potential consequence of progressive degeneration and eventual cell death.
[More]
A randomized controlled trial demonstrates improved outcomes if patients with Parkinson’s disease are cared for by a multidisciplinary team.
[More]
Great Lakes NeuroTechnologies (GLNT) announced today that they are launching a study to determine the feasibility of using intelligent algorithms to assist with programming deep brain stimulation settings for Parkinson’s disease.
[More]
A new initiative aims to accelerate the search for biomarkers - changes in the body that can be used to predict, diagnose or monitor a disease - in Parkinson's disease, in part by improving collaboration among researchers and helping patients get involved in clinical studies.
[More]
Parkinson’s disease is a neurological condition that is caused when brain cells, that produce the chemical messenger dopamine, start to die.
[More]
Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy.
[More]
Individuals with late-stage Parkinson's disease and other related motor disorders experience severe symptoms of physical and psychologic distress, suggesting that current care is falling short, say UK researchers.
[More]
Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.
[More]
On Sunday morning, the clocks will fall back to mark the official end of daylight savings time. Northwestern Medicine sleep experts warn that the one hour time shift can be disruptive to sleep patterns, but that it also offers an excellent opportunity to evaluate and improve sleep patterns.
[More]